Beta
271782

COVID-19 among Rheumatoid Arthritis Patients on ‎Immunosuppressive Therapy During the First Wave of the COVID-‎‎19 Pandemic: a Prospective Comparative Study ‎

Article

Last updated: 22 Jan 2023

Subjects

-

Tags

Infectious diseases

Abstract

Background and aim of the work: COVID-19 has multiple challenges among risky cases like rheumatoid arthritis patients. So, this ‎study was done to look for COVID-19 in patients with rheumatoid arthritis and compare the severity ‎and outcome of COVID-19 in rheumatoid arthritis patients to those in other groups‎‎‎.
Patients and Methods: the prospective comparative study included 146 randomly selected patients attending Zagazig ‎University Hospital in Egypt ,who were treated by the Egyptian Ministry of Health and Population ‎protocol for COVID-19, and the disease-modifying antirheumatic drugs (DMARDs)who fulfilled the ‎selection criteria to be recruited into three groups: rheumatoid arthritis (RA) patients; rheumatoid ‎arthritis with COVID-19 patients (RA-COVID); and a COVID-19 (COVID-19) group‎.‎
Results: the mean age of the studied group was 50 years old. The three studied groups showed no statistically significant difference (p > 0.05) as regards age, sex, level of education, and marital status. But there was a statistically significant difference between groups regarding occupation and special habits in the form of hashish smoking. There was no marked difference in COVID-19 symptoms between group II and group III. The mean of the Modified Health Assessment Questionnaire (MHAQ) was 5.5 in RA group versus 8 in RA-COVID-19 group ,with statistically significant difference between group I and II as regard DAS28. The duration from being diagnosed with COVID-19 till recovery was significantly higher in RA-COVID-19 cases compared to COVID-19.  RA-COVI-19 group did tend toward higher hospital admission rates (OR 0.81; 95% CI 0.35-0.88; p = 0.03)‎‎‎‎‎‎‎‎.
Conclusion: COVID-19 is accompanied by non-significant worsening of symptoms in RA patients on DMARDs, ‎except the admission rates. More research into expanding cases is required‎ ‎‎‎‎‎‎‎.

DOI

10.21608/aeji.2022.169271.1262

Keywords

COVID-19, Rheumatoid Arthritis, DMARD

Authors

First Name

Amgad

Last Name

Rabia

MiddleName

M

Affiliation

Head of Drug Discovery & Clinical Research Department, Dikernis ‎General Hospital (DGH), Dakahlia Governorate, Egypt

Email

dr.amgadrabie@gmail.com

City

-

Orcid

0000-0003-3681-114X

First Name

Samar

Last Name

Amer

MiddleName

A

Affiliation

Public Health and Community Medicine Department, Faculty of ‎Medicine, Zagazig University, Zagazig, Egypt.Membership at Royal Colleague of General Practice [INT], ‎London, United Kingdom.

Email

dr_samar11@yahoo.com

City

-

Orcid

https://orcid.org/00

First Name

Hosam

Last Name

Dawod

MiddleName

M

Affiliation

Tropical Medicine Department, Faculty of Medicine, Zagazig ‎University, Egypt.‎Consultant Gastroentrology, Ministry Of Health, Sultanate of Oman

Email

hosamgastro@yahoo.com

City

-

Orcid

https://orcid.org/00

First Name

Youmna

Last Name

Amer

MiddleName

A

Affiliation

Rheumatology and Rehabilitation Department, faculty of medicine, ‎Zagazig University,Egypt.

Email

hossamgastro@yahoo.com

City

-

Orcid

-

Volume

12

Article Issue

4

Related Issue

37615

Issue Date

2022-12-01

Receive Date

2022-11-02

Publish Date

2022-12-01

Page Start

410

Page End

419

Print ISSN

2090-7613

Online ISSN

2090-7184

Link

https://aeji.journals.ekb.eg/article_271782.html

Detail API

https://aeji.journals.ekb.eg/service?article_code=271782

Order

13

Type

Original Article

Type Code

616

Publication Type

Journal

Publication Title

Afro-Egyptian Journal of Infectious and Endemic Diseases

Publication Link

https://aeji.journals.ekb.eg/

MainTitle

-

Details

Type

Article

Created At

22 Jan 2023